Effectiveness of botulinum neurotoxin type A injections in naïve and previously-treated patients suffering from Torti- or Laterocollis or -caput: Results from a German-Austrian open-label prospective post-marketing surveillance study
Autor: | B. Haslinger, Pascal Maisonobe, A. Stenner, M. Müngersdorf, Wolfgang H. Jost, A. Schramm, M. Koch, P. Schwingenschuh |
---|---|
Rok vydání: | 2019 |
Předmět: |
Adult
Male medicine.medical_specialty Population Acetylcholine Release Inhibitors Postmarketing surveillance Young Adult 03 medical and health sciences 0302 clinical medicine Quality of life Germany Internal medicine Product Surveillance Postmarketing Humans Medicine Prospective Studies 030212 general & internal medicine Cervical dystonia Botulinum Toxins Type A education Torticollis Aged Aged 80 and over education.field_of_study business.industry Botulinum Neurotoxin Type A Middle Aged medicine.disease ddc Treatment Outcome Neurology Austria Quality of Life Female Neurology (clinical) Open label business Previously treated 030217 neurology & neurosurgery |
Zdroj: | Journal of the Neurological Sciences. 399:44-50 |
ISSN: | 0022-510X |
DOI: | 10.1016/j.jns.2019.02.017 |
Popis: | AbobotulinumtoxinA (aboBoNT-A; Dysport®) is an effective treatment for cervical dystonia (CD) with a well-established safety profile. In this prospective, multicentre, non-interventional study ( NCT01840462 ) the primary objective was effectiveness (Tsui score) of aboBoNT-A in botulinum neurotoxin type A (BoNT-A) treatment-naive and previously-treated (>2 yrs) patients after two injection cycles (at visit 3). Secondary objectives included the effectiveness of aboBoNT-A overall visits and quality of life (CDQ-24) in different CD subtypes. Observation time was 12–16 months, including 5 visits and 4 injection cycles (each 3–4 months). In the analysis population 273 patients from 41 centres across Germany and Austria were included. At baseline, 62.6% were previously-treated with BoNT-A. The major primary components of CD were torticollis (64.5%) and torticaput (17.6%). Previously-treated patients showed a slight reduction of the Tsui scores, whereas BoNT-A-naive patients had a more severe baseline Tsui score and improved much more over all cycles. Results were similar for CDQ-24. Interestingly, improvements mainly occurred in the Tsui subscore A (amplitude of sustained posture). Marked differences between CD subtypes regarding effectiveness could not be determined. To our knowledge this is the first large multi-centre study investigating the effectiveness of BoNT-A in different primary subtypes of CD over several injection cycles. |
Databáze: | OpenAIRE |
Externí odkaz: |